Distribution of lipid microsphere preparations

Advanced Drug Delivery Reviews

Volumn 20, Issue 2-3, 1996, Pages 147-154

  Igarashi, R ^a   Takenaga, M ^a   Matsuda, T ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Distribution; Drug carrier; Drug delivery system (DDS); Lipid microsphere (LM); Oil water emulsion; Targeting

Indexed keywords

CELLS; DISEASES; DRUG PRODUCTS; DRUG THERAPY; EMULSIONS; LASER APPLICATIONS; PHARMACOKINETICS; STABILITY;

CONFOCAL LASER IMAGING; DRUG CARRIER; DRUG DELIVERY SYSTEM; DRUG TARGETING; IN VITRO STUDY; IN VIVO STUDY; LIPID MICROSPHERES; LIPO PREPARATIONS; LIPO STEROID; OIL WATER EMULSION;

LIPIDS;

7 (3 BENZENESULFONAMIDOBICYCLO[2.2.1]HEPT 2 YL) 5 HEPTENOIC ACID; DEXAMETHASONE 21 PALMITATE; DOMITROBAN; DRUG CARRIER; FLURBIPROFEN AXETIL; GLYCEROL; ISOCARBACYCLIN METHYL ESTER; LIPID; LIPOPROSTAGLANDIN E1; LIPOSOME; MICROSPHERE; PHOSPHATIDYLCHOLINE; PROSTACYCLIN; PROSTAGLANDIN E1; SOYBEAN OIL; STEROID; TECHNETIUM 99M; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; WATER;

ANIMAL MODEL; ARTICLE; BUERGER DISEASE; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG UPTAKE; EMULSION; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; KUPFFER CELL; MACROPHAGE; NEUTROPHIL; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARMACEUTICS; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS; SPLEEN CELL; SPONTANEOUSLY HYPERTENSIVE RAT; TISSUE DISTRIBUTION; TUMOR CELL; VASCULAR ENDOTHELIUM; VASCULAR LESION;

EID: 0030602781     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-409X(95)00125-Q     Document Type: Review

References (28)

1. [1] Mizushima, Y. and Igarashi, R. (1991) Lipid microspheres and lecithinized polymer and drug delivery systems. In: (Dunn and Ottenbrite Eds.) Polymeric Drugs and Drug Delivery Systems. 267-274, American Chemical Society.
2. [2] Gregoriadis, G. and Ryman, B.E. (1971) Liposomes as carriers of enzymes or drugs: a new approach to the treatment of storage disease. Proc. Biochem. Soc. 124, 58.
3. [3] Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A. and Barenholz, Y. (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene glycol-coated liposomes. Cancer Res. 54(4), 987-992.
4. [4] Wong, JP., Stadnyk, L.L. and Saravolac, E.G. (1994) Enhanced protection against respiratory influenza A infection in mice by liposome-encapsulated antibody. Immunology 81(2), 280-284.
5. [5] Kato, K., Yoneda, Y., Okada, Y., Kiyama, H. and Shiosaka, S. (1994) Gene transfer and the expression of a foreign gene in vivo in post-mitotic neurons of the adult rat brain using the hemagglutinating virus of the Japan-liposome method. Mol. Brain Res. 25(3-4), 359-363.
6. [6] Von der Leyen, HE., Gibbons, GH., Morishita, R., Lewis, NP., Zhang, L., Nakajima, M., Kaneda, Y., Cooke, J.P. and Dzau, V.J. (1995) Gene therapy inhibiting neointimal vasucular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc. Natl. Acad. Sci. USA 92(4), 1137-1141.
7. [7] Shoji, Y., Mizushima, Y., Yanagawa, A. and Yonaha, T. (1985) Electron microscopic studies on tissue distribution of lipid microspheres used as drug delivery carriers. Drugs Exptl. Clin. Res. 11, 601-609.
8. [8] Shoji, Y., Mizushima, Y. and Kametani, T. (1986) Affinity of lipid microshere for MM46 tumor cells. Jpn. J. Pharm. Soc. 106, 605-608.
9. [9] Suzuki, K., Takahashi, K., Matsuki, Y., Kawakami, M., Kawaguchi, Y., Hidaka, T., Sekiyama, Y., Mizukami, Y., Kawagoe, M. and Nakamura, H. (1992) Fluorescent probe-labeled lipid microsphere uptake by human endothelial cells: A flow cytometric study. Jpn. J. Pharmacol. 60, 349-356.
10. [10] Suzuki, K. Activated CD4+ T cells preferentially take up lipid microspheres but resting cells do not. Clin. Exp. Immunol. in press.
11. 1 to vascular lesions. Prostagl. Leukotr. Essent. Fatty Acids 41, 269-272.
12. 99mTc-labeled lipid microspheres(LM) would be useful for an imaging study of those diseases. Jpn. J. Inflamm. 7, 551-557.
13. [13] Mizushima, Y. (1991) Lipo-prostaglandin preparation. (Review) Prostagl. Leukotr. Essent. Fatty Acids. 42, 1-6.
14. 1 incorporated in lipid microspheres, in peripheral vascular disease secondary to connective tissue disoders. J. Rheumatology 14(1), 97-101.
15. 1 prodrug for targeting therapy. J. Controlled Release 20, 37-46.
16. [16] Mizushima, Y. and Hoshi, K. (1993) Recent advances in lipid microsphere technology for targeting prostaglandin delivery (Review). J. Drug Targeting 1, 93-100.
17. [17] Mizushima, Y., Igarashi, R., Hoshi, K., Sim, A. K., Cleland, M. E., Hayashi, H. and Goto, J. (1987) Marked enhancement in antithrombotic activity of isocarbacyclin following its incorporation into lipid microspheres. Prostaglandins 33(2), 161-168.
18. [18] Grose, R., Greenberg, M., Strain, J. and Mueller, H. (1985) Intracoronary prostacyclin in evolving acute myocardial infarction. Am. J. Cardiology 55, 1625-1626.
19. [19] Gryglewski, R.J. (1985) Effects of prostacyclin in atherosclerotic vascular disease, Adv. Prostagl. Tromboxane Leukotr. Res. 15, 539-542.
20. [20] Mizushima, Y., Hamano, T. and Yokoyama, K. (1982) Tissue distribution and anti-inflammatory activity of corticosteroids incorporated in lipid emulsion. Ann. Rheum. Dis. 41, 263-267.
21. [21] Kuriyama, K., Hiyama, Y., Aoyama, Y., Ichikawa, K., Okumura, M., Masumoto, S., Ito, K., Ohtaki, Y., Hirata, M., Hanada, S., Uchida, T., Fujino, Y. and Watanabe, M. (1989) Pharmacological studies of a non-steroidal analgesic and antipyretic drug of LFP83. Folia Pharmacol. Japon 93, 61-73.
22. 2 receptor antagonist aerosol for inhalation. J. drug Targeting 1, 293-301.
23. [23] Narisada, M., Ohtani, M., Watanabe, F., Uchida, K., Arita, H., Doteuchi, M., Hanasaki, K., Kakushi, H., Otani, K. and Hara, S. (1988) Synthesis and in vitro activity of various derivatives of a novel thromboxane receptor antagonist, ( ± )-(5Z)-7(3-endo-phenylsul-fonylamino[2.2.1]bicyclohept-2-exoyl) heptenoic acid. J. Med. Chem. 31, 1847-1854.
24. 2 receptor antagonist, S-145, on isolated monkey and cat arteries. J. Cardiovasc. Pharmacol. 14, 502-509.
25. 2 receptor antagonist, S-145, on collagen-induced ECG changes and thrombocytopenia in rodents. Jpn. J. Pharmacol. 50, 195-205.
26. [26] Akutsu, I., Fukuda, T., Majima, K. and Makino, S. (1992) Inhibitory effect of inhaled FK-506 on increased bronchial responsiveness and eosinophil infiltration in the airway mucosa. Jpn. J. Allergy 41, 543-546.
27. [27] Azzawi, M., Bradley, B.L., Jeffery, P.K., Frew, A.J., Wardlaw, A.J., Knowles, G., Assoufi, B., Collins, J.V., Durham, S.R. and Kay, A.B. (1990) Identification of activated T-lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am. Rev. Respir. Dis. 142, 1407-1413.
28. [28] Bentley, A.M., Maestrelli, P., Saetta, M., Fabbri, L.M., Robinson, D.S., Bradley, B.L., Jeffery, P.K., Durham, S.R. and Kay, A.B. (1992) Activated T-lymphocytes and eosinophils in the bronchial mucosa in isocyanate-induced asthma. J. Allergy Clin. Immunol. 89, 821-829. (Review concerning lipid microsphere preparations)